AlbertTLeungMD

PubMed

• 11 citations
  Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture ...
  H G Bone, D W Dempster, J A Eisman, S L Greenspan, M R McClung
  Osteoporosis International. 2015-02-01
• 38 citations
  Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled T...
  Sydney Lou Bonnick, Tobias De Villiers, Alberto Odio, Santiago Palacios, Roland Chapurlat
  The Journal of Clinical Endocrinology and Metabolism. 2013-09-24

Journal Articles

• A Phase IIb, randomized, placebo-controlled, dose-ranging study of MK-5442 in the treatment of postmenopausal women with osteoporosis  
  Halse J, Greenspan S, Cosman F, Ellis G, Scott B, Heyden N, Doleckyj S, Samanta S, He W, Santora A, Leung A, Denker A, J Clin Endo Metab, 8/1/2014
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study  
  Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, DaSilva C, Rosenberg E, Leung A, J Bone Miner Res, 11/1/2012
• Randomized, active-controlled study of once-weekly alendronate 280-mg high-dose oral buffered solution for treatment of Paget's disease  
  Hooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, Wu M, Salzmann G, West J, Leung A, Osteoporos Int, 1/1/2009
• Agonist-dependent phosphorylation of the parathyroid hormone/parathyroid hormone-related peptide receptor  
  Qian F, Leung A, Abou-Samra A, Biochemistry, 5/1/1998
• Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction  
  Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB, Biochemistry, 10/1/1997
• Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/28 cells  
  Xie LY, Leung A, Segre GV, Yamamoto I, Abou-Samra AB, Am J Physiol, 4/1/1996
• Images in clinical medicine Vertebral osteomyelitis  
  Artinian MA, Leung AT, Tishler PV, N Engl J Med, 8/1/1993
• Subcellular distribution of the 1,4-dihydropyridine receptor in rabbit skeletal muscle in situ: an immunofluorescence and immunocolloidal gold-labeling study  
  Jorgensen AO, Shen AC, Arnold W, Leung AT, Campbell KP, J Cell Biol, 7/1/1989
• Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel  
  Ellis SB, Williams ME, Ways NR, Brenner R, Sharp AH, Leung AT, Campbell KP, McKenna E, Koch WJ, Hui A, et al, Science, 9/1/1988
• Biochemical and ultrastructural characterization of the 1,4-dihydropyridine receptor from rabbit skeletal muscle Evidence for a 52,000 Da subunit  
  Leung AT, Imagawa T, Block B, Franzini-Armstrong C, Campbell KP, J Biol Chem, 1/1/1988
• Identification and characterization of the dihydropyridine-binding subunit of the skeletal muscle dihydropyridine receptor  
  Sharp AH, Imagawa T, Leung AT, Campbell KP, J Biol Chem, 9/1/1987
• Structural characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca2+ channel from rabbit skeletal muscle Evidence for two distinct high molecu...  
  Leung AT, Imagawa T, Campbell KP, J Biol Chem, 6/1/1987
• Join now to see all

Abstracts/Posters

• Eight Years of Continued Odanacatib Therapy for Postmenopausal Women with Low Bone Mineral Density: Results from an Open-Label Extension to a Phase IIB Study.
  Rizzoli R, Rodriguez Portales JA, Benhamou CL, Halse J, Miller PD, Reid I, Dasilva C, Kroon R, Leung A, Gurner D, Osteoporos Int, 1/1/2014
• Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
  Papapoulos S, McClung M, Langdahl B, Saag K, Adami S, Bone H, de Villiers T, Kiel D, Kung A, Kumar P, Lim S-K, Ling X, Lippuner K, Mautalen C, Nakamura T, Reginster J-..., J Bone Miner Res, 1/1/2014
• Odanacatib Anti-Fracture Efficacy And Safety In Postmenopausal Women With Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
  McClung M, Langdahl B, Papapoulos S, Saag K, Adami S, Bone H, de Villiers T, Kiel D, Kung A, Kumar P, Lim S-K, Ling X, Lippuner K, Mautalen C, Nakamura T, Reginster J-..., J Bone Miner Res, 1/1/2014
• The results of a double-blind, randomized, Phase 2 dose-finding study of odanacatib, a potent cathepsin-K inhibitor, in Japanese patients with osteoporosis with a mode...
  Uchida S, Shiraki M, Fukunaga M, Tomomitsu T, Fujimoto G, Nakagomi M, Leung A, Zajic S, Santora A, Stone J, Passarell J, Nakamura T, J Bone Miner Res, 1/1/2012
• Phase 3 Fracture Trial of odanacatib for osteoporosis – baseline characteristics and study design.
  Papapoulos S, Bone H, Dempster D, Eisman J, Greenspan S, McClung M, Nakamura T, Shih J, Leung A, Santora A, Verbruggen N, Rosenberg E, Lombardi A, J Bone Miner Res, 1/1/2012
• A Phase IIb, randomized, placebo-controlled, dose-ranging study of MK-5442 in the treatment of postmenopausal women with osteoporosis.
  Halse J, Greenspan S, Cosman F, Ellis G, Scott B, Heyden N, Doleckyj S, Samanta S, He W, Santora A, Leung A, Denker A, J Bone Miner Res, 1/1/2012
• Effects of odanacatib on BMD and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate.
  De Villiers T, Bonnick S, Odio A, Palacios S, Chapurlat R, Scott B, Le Bailly De Tilleghem C, DaSilva C, Leung A, Gurner D, J Bone Miner Res, 1/1/2012
• A Phase IIb study of MK-5442 calcium sensing receptor (CaSR) antagonist in bisphosphonate-treated patients.
  Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Scott B, He W, McGinnis J, Heyden N, Samanta S, Pong A, Santora A, Leung A, Denker A, J Bone Miner Res, 1/1/2012
• BMD Response in the Odanacatib Phase 2 Trial: Prespecified Threshold and Subgroup Analyses.
  McClung M, Binkley N, Bone H, Miller P, Verbruggen N, DaSilva C, Rosenberg E, Leung A, Endo Rev, 1/1/2012
• Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: year 4 results.
  Leung A, Petrovic R, DaSilva C, Rosenberg E, Santora A, Lombardi A, J Rheumatology, 1/1/2011
• Semi-mechanistic PK/PD model of the effect of odanacatib, a cathepsin K inhibitor, on bone turnover to characterize lumbar spine bone mineral density in two Phase II S...
  Stone J, Duong L, Leung A, Fiedler-Kelly J, Jaworowicz D, Cohn D, Verbruggn N, Passarell J, Stoch A, Zajic S, J Bone Miner Res, 1/1/2010
• Phase 3 Fracture Trial of odanacatib for osteoporosis - study design.
  Bone H, Dempster D, Eisman, JA, Greenspan S, McClung M, Nakamura T, Papapoulos S, Shih J, Lombardi A, Santora A, Verbruggen N, Rosenberg E, Leung A, Endo Rev, 1/1/2010
• Effect of topiramate on bone resorption in adults.
  Ramsay ER, Leung AT, Epilepsia, 1/1/2006
• Fracture healing in patients treated with rofecoxib and nonselective NSAIDS.
  Reicin AS, Krupa D, Connors LG, Leung AT, Arthritis and Rheumatism, 9/1/2003
• Efficacy of Fosamax vs. evista comparison trial (EFFECT-international): Results at 6 months.
  Sambrook P, Geusens P, Keraudren V, Gaines K, Leung A, Melton M, Bone, 5/1/2003
• Treatment with alendronate 70-mg once weekly for 12 months increases bone mineral density and decreases biochemical markers of bone turnover in men with osteoporosis.
  Miller P, Orwoll E, Vandormael K, MacIntyre B, Smith M, Leung A, Osteo Intl, 1/1/2003
• Treatment with alendronate 70-mg once weekly for 3 months decreases biochemical markers of bone turnover in men with osteoporosis.
  Miller P, Orwoll E, Czachur M, MacIntyre B, Leung A, J Bone Miner Res, 1/1/2002
• Two-year gastrointestinal safety and tolerability of alendronate 70mg once weekly.
  Genco RJ, Van Dyke T, Leung A, Meng L, Ritter S, Grossman S, Salzmann G, Lombardi A, J Bone Miner Res, 1/1/2001
• A randomized, double-blind, placebo-controlled endoscopy study comparing the effects of alendronate once-weekly and placebo on the upper gastrointestinal mucosae.
  Lanza F, Schwarz H, Sabba B, Winograd S, Torosis J, Musliner T, Ouan H, Reyes R, Leung A, J Bone Miner Res, 1/1/2000
• Update of alendronate safety in clinical trials.
  Leung A, Heyden N, Czachur M, Gilbert J, Daifotis A, Yates AJ, J Bone Miner Res, 1/1/1999
• Alendronate prevents periprosthetic bone loss - 2 year results.
  Scammell B, Lyons A, Czachur M, Gilbert J, Freedholm D, Malbecq W, Miller C, Carr A, Checkley L, Leung A, J Bone Miner Res, 1/1/1999
• Join now to see all

Other

• Thesis: The structural and functional characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca2+ channel from rabbit skeletal muscle. 
  Leung A, University of Iowa, Iowa City, IA
  1/1/1988
• Liquid Bisphosphonate Formulations for Bone Disorders 
  Daifotis A, Denker A., Bergquist P., and Leung A, U.S. Application No. 10/305868, Case 20921Y
• Dihydropyridine Receptor and Antibodies Thereto 
  Campbell KP, Imagawa T, and Leung AT, United States Patent Number 4,912,202